此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

2015年6月19日 更新者:Lee's Pharmaceutical Limited

A Phase I Dose Escalating Study Evaluating the Pharmacokinetics, Tolerability and Safety of Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Phase 1 study to investigate safety of istaroxime in healthy chinese volunteers.

研究概览

地位

未知

条件

详细说明

32 subjects (F: M=1:1) were randomized in three dose groups (0.25-0.5-1.0ug/kg/min). 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; 12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic. At least 1 week should be kept between two dose groups. Escalation to the higher dose will occur after the lower dose group has been completed and no significant safety issues are found.

研究类型

介入性

注册 (预期的)

32

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Ruihua Dong, MD
  • 电话号码:+86-10-66947798

研究联系人备份

  • 姓名:Hengyan Qu, MD
  • 电话号码:+86-10-66947798

学习地点

      • Beijing、中国、100071
        • 招聘中
        • The 307th Hospital of Chinese People's Liberation Army
        • 接触:
          • Ruihua Dong, MD
          • 电话号码:+86-10-66947798
        • 接触:
          • Hengyan Qu, MD
          • 电话号码:+86-10-66947798

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age at 18-45 years (inclusive)
  2. Male or Non-pregnant, non-lactating women
  3. Chinese healthy subjects
  4. Body mass index (BMI) at 19-24 kg/m2 (inclusive) and body weight at 50-100kg
  5. Lab examinations (include but not limited: Hemoglobin, white blood cell counting, differential count, creatinine,Alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT),Total bilirubin and urinalysis) are within normal range or out of normal range but no clinical significance.
  6. Vital signs in screening phase: SBP100-139mmHg, DBP 50-89 mmHg, pulse rate 45-90 bpm. Holter is within normal range or out of normal range but no clinical significance.
  7. Both physical examination and ECG at baseline are normal or abnormal but no clinical significance
  8. Women of childbearing age during the trial must be willing to use a medically acceptable method of contraception, which include surgical sterilization (tubal ligation / hysterectomy), and double barrier methods of hormonal contraception.
  9. Subjects well communicate with investigators, understanding the requirements of investigators and being willing to sign the ICF before conducting any study-related procedure.
  10. Subjects are willing to stay at the phase I ward throughout the study.

Exclusion Criteria:

  1. Disease history in liver, kidney, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal tract, lungs, immune, skin, blood, or metabolic disorders or cancer, that may have great impact on the study results.
  2. Presence of pancreatitis, intestinal obstruction, glaucoma, prostatic hypertrophy, adrenal disease, hyperthyroidism or gallbladder disease (subjects had experienced cholecystectomy will not be excluded)
  3. History of clinical significant disease in the past 4 weeks before screening visit
  4. Presence of diseases which are known to disturb the absorption, distribution, metabolism or excretion of Istaroxime
  5. Physical examinations, medical history, ECG, vital signs or lab examination are deemed to be abnormal and clinical significant
  6. Be intolerant or allergy to Istaroxime, lactose or any similar substances
  7. Significantly abnormal diets are conducted within 4 weeks before screening visit
  8. Blood donation or loss equal to or exceeds 400ml in the past 6 months
  9. Participating in the any other drug study in the past 3 months
  10. Administrated OTC drugs including vitamin supplements and herbal (Occasional use of paracetamol will not be excluded)
  11. Regular use of any prescription drug (Hormonal birth control pills or hormone replacement therapy will not be excluded)
  12. Drinking beverage or eat food containing caffeinated / xanthine or poppy seed since 48 hours before study drugs administration; or drinking beverage or eat food containing grapefruit, oranges or Chinese tea 14 days before the study drug administration
  13. Receiving the therapy of drugs including cytochrome P450 3A4 or cytochrome P450 2C8 inhibitors or inducers (eg barbiturates, carbamazepine, erythromycin, phenytoin, thiazoline TZDs, Rifampin)
  14. Women at Lactation period or with positive pregnancy test
  15. Tongue piercing or lip piercing occurred 30 days before the study drug administration
  16. Smoke or tobacco is used 60 days before the study drug administration
  17. History of abusing any substance including infusion drugs, alcohol and opium
  18. Positive alcohol breathing test within 1day or drink alcohol within 1week
  19. Abusing drugs (include Opioids, oxycodone, methamphetamine, amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines class, methadone, buprenorphine and phencyclidine)
  20. History of heart disease
  21. Planning to be pregnant in the recent 3 months
  22. Participating any other interventional strudy in the past 30 days
  23. History of bronchial asthma or blood porphyria disease
  24. HbsAg, anti-HCV, anti-HIV or anti - syphilis are positive
  25. Holter examination is abnormal and clinical significant
  26. Subjects are not eligible for the study judged by investigators

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:low dose group
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
实验性的:mid dose group
12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
infusion for 24 hours
实验性的:high dose group
12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
infusion for 24 hours

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
safety of istaroxime in healthy volunteers is measured by varition of heart functon, blood pressure and heart ratio
大体时间:one week
safety of istaroxime in healthy volunteers is measured by
one week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年5月1日

初级完成 (预期的)

2015年7月1日

研究完成 (预期的)

2015年8月1日

研究注册日期

首次提交

2015年6月17日

首先提交符合 QC 标准的

2015年6月19日

首次发布 (估计)

2015年6月22日

研究记录更新

最后更新发布 (估计)

2015年6月22日

上次提交的符合 QC 标准的更新

2015年6月19日

最后验证

2015年6月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • CVie2015001

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅